Welcome to our dedicated page for Genmab SEC filings (Ticker: GMAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Genmab A/S (GMAB) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a foreign private issuer listed on Nasdaq. Genmab files annual reports on Form 20‑F and furnishes current reports on Form 6‑K under the Securities Exchange Act of 1934. These filings cover a wide range of topics, from interim financial results and capital increases to equity awards, articles of association and material company announcements.
Recent Forms 6‑K referenced in the available data include interim reports, company announcements about net sales of partnered products such as DARZALEX, capital increases resulting from employee warrant exercises, grants of restricted stock units and warrants, and disclosures related to the proposed acquisition of Merus N.V. and associated financing. Other 6‑K filings incorporate company announcements on regulatory milestones for EPKINLY (epcoritamab‑bysp), portfolio prioritization decisions and updates on late‑stage clinical programs.
Because Genmab uses its 6‑K reports to furnish key announcements to U.S. investors, these filings can be a primary source for understanding changes in its capital structure, details of tender offers and acquisitions, and the status of important clinical and commercial programs. On Stock Titan, users can review these documents alongside AI‑powered summaries that explain the context and main points of each filing, helping to interpret technical content in forms such as 6‑K and 20‑F.
Investors researching GMAB can use this page to follow how Genmab reports on its antibody platforms, collaborations, late‑stage pipeline, financing arrangements and governance documents over time. The combination of real‑time EDGAR updates and AI‑generated insights is intended to make it easier to navigate lengthy filings and identify information relevant to Genmab’s business and capital markets activity.
Genmab A/S provides an update on its ongoing share buy-back program, which was initiated to repurchase up to 342,130 shares for a maximum of DKK 725 million to honor commitments under its Restricted Stock Unit program.
From February 23 to 27, 2026, Genmab repurchased 18,000, 12,000, 15,000, 20,000 and 20,000 shares on successive trading days, at average prices between DKK 1,825.23 and DKK 1,856.49, for total consideration of DKK 156,630,920 during this period and DKK 271,855,470 accumulated under the program. Following these transactions, Genmab holds 2,763,851 treasury shares, equal to 4.30% of its total share capital and voting rights.
Genmab A/S filed a Form 6-K detailing new equity compensation grants and related insider transaction disclosures. The board granted 587,495 restricted stock units to management and employees and 455,004 warrants to employees of Genmab and its subsidiaries.
Each restricted stock unit is granted cost-free, represents a conditional right to one Genmab share of nominal DKK 1, and has a fair value equal to the grant-date closing share price of DKK 1,848.50. These RSUs generally vest three years after grant, with executive management awards linked to forward-looking performance criteria.
The warrants are also granted cost-free, have an exercise price of DKK 1,848.50 per share, a calculated fair value of DKK 594.08 using the Black-Scholes formula, vest after three years and expire seven years from grant. The filing also itemizes grants to key individuals, including CEO Jan G. J. van de Winkel and CFO Anthony Pagano, under market abuse regulation disclosure rules.
Genmab A/S filed a Form 6-K as a foreign private issuer for February 2026. The report primarily furnishes an updated corporate document, listing the company’s Articles of Association as Exhibit 3.1. The filing is also incorporated by reference into several existing Genmab Form S-8 registration statements.
Genmab A/S is making a small share capital increase after employees exercised warrants, issuing 12,313 new shares. The new shares were subscribed for cash at various prices between DKK 1,147.50 and DKK 1,615.00 per share, generating approximately DKK 17.1 million in proceeds for the company.
The new shares equal about 0.02% of Genmab’s existing share capital and carry the same rights as existing ordinary shares, including voting and dividend rights from subscription. After this increase, the total nominal share capital is DKK 64,250,721, corresponding to 64,250,721 shares and votes, and the new shares are expected to be listed on Nasdaq Copenhagen following registration.
Genmab A/S provides an update on its recently initiated share buy-back program. The company plans to repurchase up to 342,130 shares with a maximum aggregate value of DKK 725 million to meet obligations under its Restricted Stock Unit program, with completion expected by March 31, 2026.
From February 18 to February 20, 2026, Genmab repurchased 23,000, 25,000 and 15,000 shares, respectively, for a total consideration of DKK 115,224,550. Following these transactions, Genmab holds 2,678,851 treasury shares, representing 4.17% of its total share capital and voting rights.
Genmab A/S filed a Form 6-K reporting insider share trading by its Executive Vice President & Chief Financial Officer, Anthony Pagano. On February 19, 2026, he executed a sale of 1,100 Genmab shares on Nasdaq Copenhagen at an aggregated price of DKK 1,810.10 per share. Individual trades were carried out at prices between DKK 1,810.00 and DKK 1,811.00. The disclosure is made under Article 19 of the EU Market Abuse Regulation and covers trading by a person discharging managerial responsibilities.
Genmab A/S is convening its Annual General Meeting on March 19, 2026 in Copenhagen and outlining key proposals for shareholder approval. Shareholders will be asked to adopt the audited 2025 Annual Report, grant discharge to the Board and Executive Management, and carry forward the profit of USD 963 million to retained earnings rather than paying a dividend.
The agenda includes an advisory vote on the 2025 Compensation Report, re-election of six directors, and re-appointment of Deloitte as auditor, including a limited assurance engagement on sustainability statements. Board and committee fees for 2026 are proposed to remain at 2025 levels, with a base fee of DKK 600,000 and specified supplements for chair, deputy chair and committee roles, plus restricted stock units under the remuneration policy.
Genmab’s Board also proposes a share capital reduction by nominally DKK 1,900,000 through cancellation of 1,900,000 treasury shares that were repurchased for a total of DKK 2,473,734,807.58, at an average price of DKK 1,301.97 per share. Following this, the Articles of Association would be amended to reflect the reduced share capital, which is currently DKK 64,238,408 divided into shares of DKK 1 each, with one vote per share.
Genmab A/S is launching a share buy-back program of up to 342,130 shares with a maximum total value of 725 million DKK. The program is designed to meet obligations under the company’s Restricted Stock Unit program and will run from February 18, 2026, and is expected to end no later than March 31, 2026, unless suspended or terminated.
Genmab has given a non-discretionary mandate to Danske Bank, which will independently execute purchases on Nasdaq Copenhagen and multilateral trading facilities under EU market abuse and Safe Harbour rules. As of February 17, 2026, Genmab holds 2,615,851 treasury shares, equal to 4.07% of its share capital.
Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd report a combined 6.6% beneficial stake in Genmab A/S common stock on a Schedule 13G/A. They disclose beneficial ownership of 4,237,472 shares, with Orbis holding 4,229,662 shares and Allan Gray holding 7,810 shares.
Each firm has sole voting and dispositive power over its respective holdings and reports no shared power. They classify themselves as non-U.S. institutions equivalent to investment advisers and state the securities are held in the ordinary course of business, not to change or influence control of Genmab A/S.
Genmab A/S has filed its 2025 annual report on Form 20-F, outlining a biotech business heavily driven by antibody medicines and partnership revenues. In 2025, royalties from Johnson & Johnson on multiple myeloma drug DARZALEX accounted for 66% of revenue, with key patents beginning to expire from 2029 in major markets.
The report highlights rapid growth from 548 employees in 2019 to 3,029 by the end of 2025 and an expanded late-stage pipeline, including assets added through the Merus acquisition such as Rina-S and petosemtamab. Genmab discloses extensive risks around clinical trial failure, dependence on collaborators, manufacturing via a limited number of third-party CMOs (including Chinese suppliers), cybersecurity, ESG expectations and climate-related disruption. The company reports 64,238,408 ordinary shares outstanding (including those underlying ADSs) and prepares its financials in US dollars under IFRS Accounting Standards.